Dr. Hönle AG (HNL.F) Competitors

Isra Vision (ETR:ISR) and Dr. Hönle AG (HNL.F) (ETR:HNL) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Isra Vision and Dr. Hönle AG (HNL.F)'s net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Isra Vision and Dr. Hönle AG (HNL.F)'s top-line revenue, earnings per share and valuation.

Isra Vision has higher revenue and earnings than Dr. Hönle AG (HNL.F). Dr. Hönle AG (HNL.F) is trading at a lower price-to-earnings ratio than Isra Vision, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Isra Vision and Dr. Hönle AG (HNL.F), as reported by MarketBeat.

Isra Vision currently has a consensus price target of €50.00, indicating a potential upside of 5.71%. Dr. Hönle AG (HNL.F) has a consensus price target of €66.75, indicating a potential upside of 50.51%. Given Dr. Hönle AG (HNL.F)'s stronger consensus rating and higher probable upside, analysts plainly believe Dr. Hönle AG (HNL.F) is more favorable than Isra Vision.

Dividends

Isra Vision pays an annual dividend of €0.18 per share and has a dividend yield of 0.4%. Dr. Hönle AG (HNL.F) pays an annual dividend of €0.50 per share and has a dividend yield of 1.1%. Isra Vision pays out 41.8% of its earnings in the form of a dividend. Dr. Hönle AG (HNL.F) pays out 59.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Dr. Hönle AG (HNL.F) (ETR:HNL) and ADVA Optical Networking (ETR:ADV) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Dr. Hönle AG (HNL.F) and ADVA Optical Networking, as provided by MarketBeat.

Dr. Hönle AG (HNL.F) currently has a consensus target price of €66.75, indicating a potential upside of 50.51%. ADVA Optical Networking has a consensus target price of €8.38, indicating a potential downside of 8.27%. Given Dr. Hönle AG (HNL.F)'s stronger consensus rating and higher probable upside, equities research analysts clearly believe Dr. Hönle AG (HNL.F) is more favorable than ADVA Optical Networking.

Profitability

This table compares Dr. Hönle AG (HNL.F) and ADVA Optical Networking's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Dr. Hönle AG (HNL.F) and ADVA Optical Networking's gross revenue, earnings per share (EPS) and valuation.

ADVA Optical Networking has higher revenue and earnings than Dr. Hönle AG (HNL.F). ADVA Optical Networking is trading at a lower price-to-earnings ratio than Dr. Hönle AG (HNL.F), indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Hönle AG (HNL.F) beats ADVA Optical Networking on 6 of the 8 factors compared between the two stocks.

GFT Technologies (ETR:GFT) and Dr. Hönle AG (HNL.F) (ETR:HNL) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares GFT Technologies and Dr. Hönle AG (HNL.F)'s revenue, earnings per share (EPS) and valuation.

GFT Technologies has higher revenue and earnings than Dr. Hönle AG (HNL.F). GFT Technologies is trading at a lower price-to-earnings ratio than Dr. Hönle AG (HNL.F), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for GFT Technologies and Dr. Hönle AG (HNL.F), as reported by MarketBeat.

GFT Technologies currently has a consensus price target of €14.50, suggesting a potential downside of 7.99%. Dr. Hönle AG (HNL.F) has a consensus price target of €66.75, suggesting a potential upside of 50.51%. Given Dr. Hönle AG (HNL.F)'s higher possible upside, analysts plainly believe Dr. Hönle AG (HNL.F) is more favorable than GFT Technologies.

Dividends

GFT Technologies pays an annual dividend of €0.20 per share and has a dividend yield of 1.3%. Dr. Hönle AG (HNL.F) pays an annual dividend of €0.50 per share and has a dividend yield of 1.1%. GFT Technologies pays out 52.9% of its earnings in the form of a dividend. Dr. Hönle AG (HNL.F) pays out 59.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GFT Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares GFT Technologies and Dr. Hönle AG (HNL.F)'s net margins, return on equity and return on assets.

Summary

Dr. Hönle AG (HNL.F) beats GFT Technologies on 5 of the 9 factors compared between the two stocks.

Manz (ETR:M5Z) and Dr. Hönle AG (HNL.F) (ETR:HNL) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Profitability

This table compares Manz and Dr. Hönle AG (HNL.F)'s net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Manz and Dr. Hönle AG (HNL.F)'s revenue, earnings per share and valuation.

Dr. Hönle AG (HNL.F) has lower revenue, but higher earnings than Manz. Dr. Hönle AG (HNL.F) is trading at a lower price-to-earnings ratio than Manz, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Manz and Dr. Hönle AG (HNL.F), as reported by MarketBeat.com.

Dr. Hönle AG (HNL.F) has a consensus target price of €66.75, suggesting a potential upside of 50.51%. Given Dr. Hönle AG (HNL.F)'s higher possible upside, analysts clearly believe Dr. Hönle AG (HNL.F) is more favorable than Manz.

Summary

Dr. Hönle AG (HNL.F) beats Manz on 5 of the 7 factors compared between the two stocks.

Dr. Hönle AG (HNL.F) (ETR:HNL) and HolidayCheck Group (ETR:HOC) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Dr. Hönle AG (HNL.F) and HolidayCheck Group's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Dr. Hönle AG (HNL.F) and HolidayCheck Group's revenue, earnings per share and valuation.

Dr. Hönle AG (HNL.F) has higher revenue and earnings than HolidayCheck Group. HolidayCheck Group is trading at a lower price-to-earnings ratio than Dr. Hönle AG (HNL.F), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Dr. Hönle AG (HNL.F) and HolidayCheck Group, as reported by MarketBeat.

Dr. Hönle AG (HNL.F) currently has a consensus price target of €66.75, indicating a potential upside of 50.51%. Given Dr. Hönle AG (HNL.F)'s higher probable upside, analysts plainly believe Dr. Hönle AG (HNL.F) is more favorable than HolidayCheck Group.

Dividends

Dr. Hönle AG (HNL.F) pays an annual dividend of €0.50 per share and has a dividend yield of 1.1%. HolidayCheck Group pays an annual dividend of €0.04 per share and has a dividend yield of 1.8%. Dr. Hönle AG (HNL.F) pays out 59.3% of its earnings in the form of a dividend. HolidayCheck Group pays out -3.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. HolidayCheck Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Dr. Hönle AG (HNL.F) beats HolidayCheck Group on 6 of the 9 factors compared between the two stocks.

Wirecard (ETR:WDI) and Dr. Hönle AG (HNL.F) (ETR:HNL) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.

Profitability

This table compares Wirecard and Dr. Hönle AG (HNL.F)'s net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Wirecard and Dr. Hönle AG (HNL.F)'s revenue, earnings per share and valuation.

Wirecard has higher revenue and earnings than Dr. Hönle AG (HNL.F). Wirecard is trading at a lower price-to-earnings ratio than Dr. Hönle AG (HNL.F), indicating that it is currently the more affordable of the two stocks.

Dividends

Wirecard pays an annual dividend of €0.20 per share and has a dividend yield of 48.7%. Dr. Hönle AG (HNL.F) pays an annual dividend of €0.50 per share and has a dividend yield of 1.1%. Wirecard pays out 5.1% of its earnings in the form of a dividend. Dr. Hönle AG (HNL.F) pays out 59.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Wirecard is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Ratings

This is a summary of current recommendations and price targets for Wirecard and Dr. Hönle AG (HNL.F), as reported by MarketBeat.com.

Wirecard currently has a consensus target price of €152.07, suggesting a potential upside of 36,909.35%. Dr. Hönle AG (HNL.F) has a consensus target price of €66.75, suggesting a potential upside of 50.51%. Given Wirecard's higher possible upside, research analysts clearly believe Wirecard is more favorable than Dr. Hönle AG (HNL.F).

Summary

Wirecard beats Dr. Hönle AG (HNL.F) on 7 of the 10 factors compared between the two stocks.